PEAK6 Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

PEAK6 Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$2.25M	Buy	+136,200	New	+$2.08M	0.01%	1278
2017 Q1	–	Sell	-16,900	Closed	-$273K	–	5356
2016 Q4	$273K	Buy	16,900 +8,200	+94%	+$149K	﹤0.01%	3070
2016 Q3	$158K	Sell	8,700 -13,200	-60%	-$258K	﹤0.01%	3306
2016 Q2	$361K	Sell	21,900 -29,200	-57%	-$472K	﹤0.01%	2656
2016 Q1	$847K	Buy	51,100 +18,800	+58%	+$329K	0.01%	1824
2015 Q4	$700K	Sell	32,300 -125,600	-80%	-$2.44M	﹤0.01%	2270
2015 Q3	$3.13M	Sell	157,900 -29,700	-16%	-$938K	0.02%	1218
2015 Q2	$6.52M	Buy	187,600 +125,900	+204%	+$3.84M	0.04%	671
2015 Q1	$1.6M	Buy	+61,700	New	+$1.13M	0.01%	1469

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PEAK6 Group's HZNP Position: Q4 2016 in Review

PEAK6 Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 5,999 shares — an estimated $109K sold.

PEAK6 Group first reported a position in HZNP in Q4 2015 and held it in 2 quarters. The position peaked at $652K in Q4 2015. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

PEAK6 Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
PEAK6 Group sold 5,999 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $109K.
PEAK6 Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 2 quarters.
PEAK6 Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $652K in Q4 2015.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on PEAK6 Group's 13F filing for Q4 2016, filed 13 Feb 2017.